These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 17107236)

  • 1. Cognitive and functional effects of atypical antipsychotic medications.
    Harvey PD
    J Clin Psychiatry; 2006 Oct; 67(10):e13. PubMed ID: 17107236
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effects of clozapine on cognitive functioning in schizophrenia.
    McGurk SR
    J Clin Psychiatry; 1999; 60 Suppl 12():24-9. PubMed ID: 10372607
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Atypical antipsychotics and cognition in schizophrenia.
    Sharma T
    Arch Gen Psychiatry; 2002 Jun; 59(6):571-2; author reply 573-5. PubMed ID: 12044209
    [No Abstract]   [Full Text] [Related]  

  • 4. The effects of atypical antipsychotic drugs on neurocognitive impairment in schizophrenia: a review and meta-analysis.
    Keefe RS; Silva SG; Perkins DO; Lieberman JA
    Schizophr Bull; 1999; 25(2):201-22. PubMed ID: 10416727
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Studies of cognitive change in patients with schizophrenia following novel antipsychotic treatment.
    Harvey PD; Keefe RS
    Am J Psychiatry; 2001 Feb; 158(2):176-84. PubMed ID: 11156796
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cognitive effects of conventional and atypical antipsychotics in schizophrenia.
    Sharma T
    Br J Psychiatry Suppl; 1999; (38):44-51. PubMed ID: 10884899
    [No Abstract]   [Full Text] [Related]  

  • 7. Cognitive improvement in response to antipsychotic drugs: neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial.
    Heinrichs RW
    Arch Gen Psychiatry; 2007 Jun; 64(6):631-2. PubMed ID: 17548745
    [No Abstract]   [Full Text] [Related]  

  • 8. Cognitive improvement after treatment with second-generation antipsychotic medications in first-episode schizophrenia: is it a practice effect?
    Goldberg TE; Goldman RS; Burdick KE; Malhotra AK; Lencz T; Patel RC; Woerner MG; Schooler NR; Kane JM; Robinson DG
    Arch Gen Psychiatry; 2007 Oct; 64(10):1115-22. PubMed ID: 17909123
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Normal P50 suppression in schizophrenia patients treated with atypical antipsychotic medications.
    Light GA; Geyer MA; Clementz BA; Cadenhead KS; Braff DL
    Am J Psychiatry; 2000 May; 157(5):767-71. PubMed ID: 10784470
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Important steps in the development of cognitive-enhancing drugs in schizophrenia.
    Buchanan RW
    Am J Psychiatry; 2006 Nov; 163(11):1867-9. PubMed ID: 17074932
    [No Abstract]   [Full Text] [Related]  

  • 11. Evaluating the effects of antipsychotics on cognition in schizophrenia. Collaborative Working Group on Clinical Trial Evaluations.
    J Clin Psychiatry; 1998; 59 Suppl 12():35-40. PubMed ID: 9766618
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cognitive effects and antipsychotic treatment.
    Kasper S; Resinger E
    Psychoneuroendocrinology; 2003 Jan; 28 Suppl 1():27-38. PubMed ID: 12504070
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improvement of cognitive dysfunction after treatment with second-generation antipsychotics.
    Weiss E; Kemmler G; Fleischhacker WW
    Arch Gen Psychiatry; 2002 Jun; 59(6):572-3; author reply 573-5. PubMed ID: 12044210
    [No Abstract]   [Full Text] [Related]  

  • 14. Cognitive dysfunction in schizophrenia and its importance to outcome: the place of atypical antipsychotics in treatment.
    Velligan DI; Miller AL
    J Clin Psychiatry; 1999; 60 Suppl 23():25-8. PubMed ID: 10625197
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effects of second-generation antipsychotics on cognitive functioning and psychosocial outcome in schizophrenia.
    Weiss EM; Bilder RM; Fleischhacker WW
    Psychopharmacology (Berl); 2002 Jun; 162(1):11-7. PubMed ID: 12107611
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact on cognition of the use of antipsychotics.
    Sharma T
    Curr Med Res Opin; 2002; 18 Suppl 3():s13-7. PubMed ID: 12418607
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Symptom domains of schizophrenia: the role of atypical antipsychotic agents.
    Burton S
    J Psychopharmacol; 2006 Nov; 20(6 Suppl):6-19. PubMed ID: 17046984
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparing the effect of the subcategories of atypical antipsychotic medications on cognition in schizophrenia using a meta-analytic approach.
    Clissold M; Crowe SF
    J Clin Exp Neuropsychol; 2019 Feb; 41(1):26-42. PubMed ID: 30025491
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Social cognition [corrected] and neurocognition: effects of risperidone, olanzapine, and haloperidol.
    Sergi MJ; Green MF; Widmark C; Reist C; Erhart S; Braff DL; Kee KS; Marder SR; Mintz J
    Am J Psychiatry; 2007 Oct; 164(10):1585-92. PubMed ID: 17898351
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Executive function in schizophrenia: what impact do antipsychotics have?
    O'Grada C; Dinan T
    Hum Psychopharmacol; 2007 Aug; 22(6):397-406. PubMed ID: 17579928
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.